New injection therapy targets Hard-to-Treat cancers in early trial
NCT ID NCT05155332
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 26 times
Summary
This early-phase study tests a new experimental drug, BI 1831169, in adults with advanced solid tumors that have spread or come back. The drug is given alone or with an immunotherapy (anti-PD-1 antibody) to find the safest dose and see if it can shrink tumors. About 190 participants will receive injections or infusions every three weeks. The study is currently suspended.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina, 27157, United States
-
Banner MD Anderson Cancer Center-Gilbert-55251
Gilbert, Arizona, 85234, United States
-
CTR Eugène Marquis
Rennes, 35042, France
-
Clínica Universidad de Navarra
Pamplona, 31008, Spain
-
Edegem - UNIV UZ Antwerpen
Edegem, 2650, Belgium
-
Fundación Jiménez Díaz
Madrid, 28040, Spain
-
HOP Timone
Marseille, 13385, France
-
Hospital Duran i Reynals
L'Hospitalet de Llobregat, 08907, Spain
-
INS Bergonie
Bordeaux, 33000, France
-
Institut Gustave Roussy
Villejuif, 94805, France
-
M Health Fairview University of Minnesota Medical Center
Minneapolis, Minnesota, 55455, United States
-
Medical University of Innsbruck
Innsbruck, 6020, Austria
-
Morristown Medical Center
Morristown, New Jersey, 07960, United States
-
Orlando Health Cancer Institute
Orlando, Florida, 32806, United States
-
Peninsula Haematology & Oncology
Frankston, Victoria, 3199, Australia
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
-
Providence St. John's Health Center
Santa Monica, California, 90404, United States
-
Salzburg Cancer Research Institute
Salzburg, 5020, Austria
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
UZ Leuven
Leuven, 3000, Belgium
-
University Hospital Geneva
Geneva, 1205, Switzerland
-
University of Arizona
Tucson, Arizona, 85719, United States
-
University of California San Diego
La Jolla, California, 92037, United States
-
University of Colorado Denver
Aurora, Colorado, 80045, United States
-
Universitätsklinikum Tübingen
Tübingen, 72076, Germany
-
Universitätsklinikum Ulm
Ulm, 89081, Germany
Conditions
Explore the condition pages connected to this study.